Metalloproteinase inhibitors: biological actions and therapeutic opportunities

Tissue inhibitors of metalloproteinases (TIMPs) are the major cellular inhibitors of the matrix metalloproteinase (MMP) sub-family, exhibiting varying efficacy against different members, as well as different tissue expression patterns and modes of regulation. Other proteins have modest inhibitory activity against some of the MMPs, including domains of netrins, the procollagen C-terminal proteinase enhancer (PCPE), the reversion-inducing cysteine-rich protein with Kazal motifs (RECK), and tissue factor pathway inhibitor (TFPI-2), but their physiological significance is not at all clear.α 2-Macroglobulin, thrombospondin-1 and thrombospondin-2 can bind to some MMPs and act as agents for their removal from the extracellular environment. In contrast, few effective inhibitors of other members of the metzincin family, the astacins or the distintegrin metalloproteinases, ADAMs have been identified. Many of these MMP inhibitors, including the TIMPs, possess other biological activities which may not be related to their inhibitory capacities. These need to be thoroughly characterized in order to allow informed development of MMP inhibitors as potential therapeutic agents. Over activity of MMPs has been implicated in many diseases, including those of the cardiovascular system, arthritis and cancer. The development of synthetic small molecule inhibitors has been actively pursued for some time, but the concept of the use of the natural inhibitors, such as the TIMPs, in gene based therapies is being assessed in animal models and should provide useful insights into the cell biology of degradative diseases.

[1]  J. Quigley,et al.  Alpha2-macroglobulin: an evolutionarily conserved arm of the innate immune system. , 1999, Developmental and comparative immunology.

[2]  Gillian Murphy,et al.  The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A , 1998, The Journal of Biological Chemistry.

[3]  U. Thorgeirsson,et al.  Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. , 1999, Biochemical and biophysical research communications.

[4]  D. Benezra.  Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. , 1997, Investigative ophthalmology & visual science.

[5]  A. Eisen,et al.  Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. , 1991, The Journal of investigative dermatology.

[6]  L. Coussens,et al.  Models for gain-of-function and loss-of-function of MMPs. Transgenic and gene targeted mice. , 2001, Methods in molecular biology.

[7]  M. Flannery,et al.  Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation. , 1996, Development.

[8]  G. Angelini,et al.  Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein , 1998 .

[9]  W. Stetler-Stevenson,et al.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. , 1998, The Journal of clinical investigation.

[10]  M. Reidy,et al.  Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. , 1994, Circulation research.

[11]  M. Reidy,et al.  Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. , 1994, Journal of vascular surgery.

[12]  J. Verheijen,et al.  Angioplasty : A Study in the Atherosclerotic Yucatan Micropig Metalloproteinase Inhibition Reduces Constrictive Arterial Remodeling After Balloon , 2000 .

[13]  A. Shinagawa,et al.  Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Journal of cell science.

[14]  W. Stetler-Stevenson,et al.  Tissue Inhibitor of Metalloproteinase-2 Stimulates Fibroblast Proliferation via a cAMP-dependent Mechanism (*) , 1995, The Journal of Biological Chemistry.

[15]  G. Marti,et al.  Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. , 1997, Blood.

[16]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[17]  M. Lim,et al.  The roles of tissue inhibitors of metalloproteinases in tissue remodelling and cell growth. , 1996, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.

[18]  E. Brown,et al.  Molecular characterization and expression of the gene encoding human erythroid-potentiating activity , 1985, Nature.

[19]  M. Kumegawa,et al.  Tissue Inhibitor of Metalloproteinases 1 and 2 Directly Stimulate the Bone‐Resorbing Activity of Isolated Mature Osteoclasts , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  R. Huber,et al.  Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 , 1997, Nature.

[21]  J. Quigley,et al.  Alpha2-macroglobulin: an evolutionarily conserved arm of the innate immune system. , 1999, Developmental and comparative immunology.

[22]  N. Colburn,et al.  TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. , 1997, Cytokine.

[23]  P. Soloway,et al.  TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo * , 2000, The Journal of Biological Chemistry.

[24]  A. Baker,et al.  Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins , 1998, Gene Therapy.

[25]  M. Reidy,et al.  Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. , 1996, Circulation research.

[26]  S. Moestrup,et al.  Alpha 2-macroglobulin-proteinase complexes, plasminogen activator inhibitor type-1-plasminogen activator complexes, and receptor-associated protein bind to a region of the alpha 2-macroglobulin receptor containing a cluster of eight complement-type repeats. , 1993, The Journal of biological chemistry.

[27]  G. Angelini,et al.  Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. , 1998, Human gene therapy.

[28]  P. Wingfield,et al.  Biophysical and Functional Characterization of Full-length, Recombinant Human Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Produced in Escherichia coli , 1999, The Journal of Biological Chemistry.

[29]  P. Slocombe,et al.  The in vitro activity of ADAM‐10 is inhibited by TIMP‐1 and TIMP‐3 , 2000, FEBS letters.

[30]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[31]  L. Patthy,et al.  The NTR module: Domains of netrins, secreted frizzled related proteins, and type I procollagen C‐proteinase enhancer protein are homologous with tissue inhibitors of metalloproteases , 1999, Protein science : a publication of the Protein Society.

[32]  M. Cilli,et al.  TIMP‐2 over‐expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis , 1998 .

[33]  B. Fingleton,et al.  Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.

[34]  A. Newby,et al.  Tissue Inhibitor of Metalloproteinase-3 Induces a Fas-associated Death Domain-dependent Type II Apoptotic Pathway* , 2002, The Journal of Biological Chemistry.

[35]  G. Cherr,et al.  Metalloproteinase Inhibition and the Response to Angioplasty and Stenting in Atherosclerotic Primates , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[36]  T. Godenschwege,et al.  Inflated wings, tissue autolysis and early death in tissue inhibitor of metalloproteinases mutants of Drosophila. , 2000, European journal of cell biology.

[37]  J. Fata,et al.  Accelerated apoptosis in the Timp-3-deficient mammary gland. , 2001, The Journal of clinical investigation.

[38]  W. Nothnick.  Reduction in reproductive lifespan of tissue inhibitor of metalloproteinase 1 (TIMP-1)-deficient female mice. , 2001, Reproduction.

[39]  K. Iwata,et al.  Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum , 1992, FEBS letters.

[40]  P. Slocombe,et al.  TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. , 1998, FEBS letters.

[41]  V. Knäuper,et al.  Localization of the Death Domain of Tissue Inhibitor of Metalloproteinase-3 to the N Terminus , 2000, The Journal of Biological Chemistry.

[42]  A. Clowes,et al.  Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. , 1996, Circulation research.

[43]  Y Ikawa,et al.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  P. Libby,et al.  Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. , 2001, The Journal of clinical investigation.

[45]  A. Rafe,et al.  TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. , 1996, Experimental cell research.

[46]  J. Geoghegan,et al.  Treatment of colorectal liver metastases , 1999, The British journal of surgery.

[47]  M. Crow,et al.  Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. , 1998, Circulation.

[48]  E. Creemers,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinase: Regulation and Dysregulation in the failing Heart Matrix M , 2022 .

[49]  C. López-Otín,et al.  Collagenase-3 Binds to a Specific Receptor and Requires the Low Density Lipoprotein Receptor-related Protein for Internalization* , 1999, The Journal of Biological Chemistry.

[50]  Oonagh Dowling,et al.  Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome , 2001, Nature Genetics.

[51]  V. Kähäri,et al.  Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. , 1998, Cancer research.

[52]  H. Birkedal‐Hansen,et al.  Inactivating Mutation of the Mouse Tissue Inhibitor of Metalloproteinases-2(Timp-2) Gene Alters ProMMP-2 Activation* , 2000, The Journal of Biological Chemistry.

[53]  P. Bornstein,et al.  The Low Density Lipoprotein Receptor-related Protein Modulates Levels of Matrix Metalloproteinase 9 (MMP-9) by Mediating Its Cellular Catabolism* , 2001, The Journal of Biological Chemistry.

[54]  M Kashiwagi,et al.  TIMP-3 Is a Potent Inhibitor of Aggrecanase 1 (ADAM-TS4) and Aggrecanase 2 (ADAM-TS5)* , 2001, The Journal of Biological Chemistry.

[55]  N. Colburn,et al.  Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. , 1996, Carcinogenesis.

[56]  P. Slocombe,et al.  TNF‐α converting enzyme (TACE) is inhibited by TIMP‐3 , 1998 .

[57]  V. Diehl,et al.  Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. , 2002, Blood.

[58]  K. Brew,et al.  Tissue inhibitors of metalloproteinases: evolution, structure and function. , 2000, Biochimica et biophysica acta.

[59]  S. Hawkes,et al.  Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[60]  D. Collen,et al.  Reduced Atherosclerotic Plaque but Enhanced Aneurysm Formation in Mice With Inactivation of the Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Gene , 2002, Circulation research.

[61]  A. Kossakowska,et al.  Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin's lymphomas. , 1991, Blood.

[62]  K. Brew,et al.  TIMP-3 Binds to Sulfated Glycosaminoglycans of the Extracellular Matrix* , 2000, The Journal of Biological Chemistry.

[63]  J. Scholefield,et al.  Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial , 2002, British Journal of Cancer.

[64]  T. Hoshino,et al.  Cell cycle-dependent localization of tissue inhibitor of metalloproteinases-1 immunoreactivity in cultured human gingival fibroblasts. , 1995, Nagoya journal of medical science.

[65]  P. D. Brown,et al.  A phase II trial of marimastat in advanced pancreatic cancer , 2001, British Journal of Cancer.

[66]  A. Baker,et al.  Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3 , 1999, British Journal of Cancer.

[67]  J. Caillaud,et al.  Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. , 1999, Circulation.

[68]  S. George,et al.  Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. , 1997, Cardiovascular research.

[69]  K. Brand,et al.  Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. , 2000, Cancer research.

[70]  I. Goldberg,et al.  Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. , 2001, Cancer research.

[71]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[72]  C. Overall,et al.  Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. , 2001, Cancer research.

[73]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[74]  H. Nagase.  Activation mechanisms of matrix metalloproteinases. , 1997, Biological chemistry.

[75]  S. George.  Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. , 1998, Current opinion in lipidology.

[76]  P. Brown.  Ongoing trials with matrix metalloproteinase inhibitors , 2000, Expert opinion on investigational drugs.

[77]  Z. Werb.  ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.

[78]  G. Angelini,et al.  Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. , 2000, Circulation.

[79]  R. Khokha,et al.  Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. , 1994, The Journal of biological chemistry.

[80]  I. Goldberg,et al.  Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA , 2001, Oncogene.

[81]  D. Edwards,et al.  TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. , 2001, Journal of the American Society of Nephrology : JASN.

[82]  K. Appelt,et al.  Matrix Metalloproteinase Inhibitors for Cancer Therapy , 2000, Cancer Drug Discovery and Development.

[83]  D. Grignon,et al.  High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. , 1996, Cancer research.

[84]  J. McEwan,et al.  Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. , 1999, Circulation.

[85]  N. Bersch,et al.  Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. , 1995, Blood.

[86]  W. Stetler-Stevenson,et al.  Tissue inhibitor of metalloproteinase‐2 (TIMP‐2) has erythroid‐potentiating activity , 1992, FEBS letters.

[87]  C. Overall,et al.  Tissue Inhibitor of Metalloproteinase (TIMP)-2 Acts Synergistically with Synthetic Matrix Metalloproteinase (MMP) Inhibitors but Not with TIMP-4 to Enhance the (Membrane Type 1)-MMP-dependent Activation of Pro-MMP-2* , 2000, The Journal of Biological Chemistry.

[88]  T. Mak,et al.  Spontaneous air space enlargement in the lungs of mice lacking tissue inhibitor of metalloproteinases-3 (TIMP-3). , 2001, The Journal of clinical investigation.

[89]  R. Grenman,et al.  Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[90]  B. Vaillant,et al.  Regulation of Hepatic Fibrosis and Extracellular Matrix Genes by the Th Response: New Insight into the Role of Tissue Inhibitors of Matrix Metalloproteinases , 2001, Journal of Immunology.

[91]  M. Davies,et al.  Upregulation of basement membrane-degrading metalloproteinase secretion after balloon injury of pig carotid arteries. , 1996, Circulation research.

[92]  S. Shapiro,et al.  Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. , 2000, The Journal of clinical investigation.

[93]  A. Baker,et al.  Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. , 1998, The Journal of clinical investigation.